Skip to main content
BDSIinactive

BIODELIVERY SCIENCES INTERNATIONAL INC

·Commercial·CEO: Jeffrey Bailey
OncologyNeurologyPainGastroenterology

BDSI evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for BDSI—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

9.1/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

—

Lead Asset

belbuca (Approved)

Next Catalyst

—

Financial data as of Dec 31, 2021.

Tracking 5 pipeline candidates · 2 FDA decisions for BIODELIVERY SCIENCES INTERNATIONAL INC.

Run BIODELIVERY SCIENCES INTERNATIONAL INC through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available BIODELIVERY SCIENCES INTERNATIONAL INC facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway10.0

Profitable (positive operating cash flow)

Financial Health7.8

D/E 0.73

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is BIODELIVERY SCIENCES INTERNATIONAL INC's lead drug candidate?

BIODELIVERY SCIENCES INTERNATIONAL INC's most advanced tracked candidate is belbuca (Approved) for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Who is the CEO of BIODELIVERY SCIENCES INTERNATIONAL INC?

Jeffrey Bailey is the chief executive officer of BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI).

What therapeutic areas does BIODELIVERY SCIENCES INTERNATIONAL INC focus on?

BIODELIVERY SCIENCES INTERNATIONAL INC develops therapies across Oncology, Neurology, Pain, Gastroenterology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.